This study is looking at whether a medicine called infliximab can help improve thinking skills in people with major depressive disorder who also have signs of inflammation (high C-reactive protein levels). Participants will receive either infliximab or a placebo (a saline solution that looks the same). Researchers will measure psychomotor speed (how fast you react) and executive function (your ability to plan and focus) over two weeks to see if infliximab makes a difference. You could be eligible if you are 25-50 years old, have major depressive disorder, and have a C-reactive protein level of 3mg/L or higher. The current status of this study is unclear, and it aims to enroll 100 participants.

Study design

This is a randomized controlled trial where 100 participants will be assigned by chance to receive either infliximab or a placebo. It is a mechanistic study, meaning it aims to understand how the treatment works.

What's involved

You would receive an intravenous infusion and have blood drawn. You would also complete brief, daily assessments on a mobile app and have in-person assessments over a two-week period.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for two weeks after treatment, with assessments of psychomotor speed and executive function.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.